First Quadrant L P CA purchased a new position in Bioverativ Inc (NASDAQ:BIVV) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 338,361 shares of the biotechnology company’s stock, valued at approximately $19,310,000. First Quadrant L P CA owned about 0.31% of Bioverativ at the end of the most recent reporting period.
Other hedge funds have also bought and sold shares of the company. TCI Wealth Advisors Inc. purchased a new stake in Bioverativ during the third quarter valued at $186,000. Reliance Trust Co. of Delaware purchased a new stake in Bioverativ during the third quarter valued at $249,000. Whittier Trust Co. of Nevada Inc. purchased a new stake in Bioverativ during the third quarter valued at $293,000. Raymond James Trust N.A. purchased a new stake in Bioverativ during the third quarter valued at $297,000. Finally, Oakbrook Investments LLC purchased a new stake in Bioverativ during the third quarter valued at $327,000. Hedge funds and other institutional investors own 95.16% of the company’s stock.
A number of research firms have recently weighed in on BIVV. Zacks Investment Research lowered Bioverativ from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Jefferies Group LLC reissued a “buy” rating and set a $70.00 price target (up from $67.00) on shares of Bioverativ in a research note on Wednesday, August 9th. Argus raised Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a research note on Wednesday, September 20th. Cowen and Company reissued a “buy” rating and set a $80.00 price target on shares of Bioverativ in a research note on Friday, August 4th. Finally, Evercore ISI initiated coverage on Bioverativ in a research note on Wednesday, August 16th. They set an “in-line” rating and a $58.00 price target for the company. One analyst has rated the stock with a sell rating, nine have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $61.73.
Bioverativ Inc (NASDAQ:BIVV) traded up $0.25 on Tuesday, reaching $53.91. The company’s stock had a trading volume of 766,700 shares, compared to its average volume of 1,622,138. Bioverativ Inc has a one year low of $40.00 and a one year high of $64.41.
Bioverativ (NASDAQ:BIVV) last announced its earnings results on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.25. The business had revenue of $291.60 million for the quarter, compared to analysts’ expectations of $285.45 million. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. The business’s revenue for the quarter was up 27.2% compared to the same quarter last year. equities analysts predict that Bioverativ Inc will post 2.45 earnings per share for the current fiscal year.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.